scholarly journals Mesenchymal stem cell applications in polycystic ovary syndrome treatment

2021 ◽  
Vol 38 (3) ◽  
pp. 361-366
Author(s):  
Mehmet Volkan BULBUL ◽  
Berna YILDIRIM ◽  
Bircan KOLBASI ◽  
İlknur KESKIN
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Polycystic Ovary Syndrome ◽  
Spinal Cord Injuries ◽  
Polycystic Ovary ◽  
Experimental Studies ◽  
Tooth Pulp ◽  
Therapeutic Effects ◽  
Ovary Syndrome ◽  
Paracrine Factors

Mesenchymal stem cells (MSCs) are highly capable of self-renewal and differentiation. They can be isolated from a variety of sources such as adipose tissue, bone marrow, umbilical cord, tooth pulp and can be cultured under in vitro conditions. MSCs have anti-inflammatory, anti-apoptotic, angiogenic, immunomodulatory and many more therapeutic effects due to the effects of paracrine factors they secrete. Today, mesenchymal stem cells are used for treatment in more than twenty diseases, from spinal cord injuries to diabetes. However, there is little mention in the literature of the use of these cells in female reproductive system diseases. In this review, a limited number of clinical and experimental studies on the use of mesenchymal stem cells in the treatment of polycystic ovary syndrome, which is very common in women, were examined and analyzed.

scholarly journals Use of Photobiomodulation and Mesenchymal Stem Cells in Polycystic Ovary Syndrome‐Induced Rats

2019 ◽  
Vol 33 (S1) ◽  
Author(s):  
Eduardo Donato Alves ◽  
Luíz Guilherme Dércore Benevenuto ◽  
Rebeca Gall Amin ◽  
João Antônio Donadoni ◽  
Kamile Bausells Ferrari ◽  
...  
Keyword(s):  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Ovary Syndrome

Therapeutic Effects of Biguanide Vs. Statin in Polycystic Ovary Syndrome: A Randomized Clinical Trial

2011 ◽  
Vol 14 (11) ◽  
pp. 658-663 ◽  
Author(s):  
Nazli Navali ◽  
Shabnam Pourabolgh ◽  
Rohollah Fadaei Fouladi ◽  
Mehri Amiri Nikpour
Keyword(s):  
Clinical Trial ◽  
Polycystic Ovary Syndrome ◽  
Randomized Clinical Trial ◽  
Polycystic Ovary ◽  
Therapeutic Effects ◽  
Ovary Syndrome

scholarly journals Anti-Fibrotic Effect of Human Wharton’s Jelly-Derived Mesenchymal Stem Cells on Skeletal Muscle Cells, Mediated by Secretion of MMP-1

2020 ◽  
Vol 21 (17) ◽  
pp. 6269
Author(s):  
Alee Choi ◽  
Sang Eon Park ◽  
Jang Bin Jeong ◽  
Suk-joo Choi ◽  
Soo-young Oh ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Wharton’S Jelly ◽  
Mdx Mice ◽  
Therapeutic Effects ◽  
Paracrine Factors ◽  
Wharton's Jelly ◽  
Muscle Fibrosis ◽  
Skeletal Muscle Fibrosis

Extracellular matrix (ECM) components play an important role in maintaining skeletal muscle function, but excessive accumulation of ECM components interferes with skeletal muscle regeneration after injury, eventually inducing fibrosis. Increased oxidative stress level caused by dystrophin deficiency is a key factor in fibrosis in Duchenne muscular dystrophy (DMD) patients. Mesenchymal stem cells (MSCs) are considered a promising therapeutic agent for various diseases involving fibrosis. In particular, the paracrine factors secreted by MSCs play an important role in the therapeutic effects of MSCs. In this study, we investigated the effects of MSCs on skeletal muscle fibrosis. In 2–5-month-old mdx mice intravenously injected with 1 × 105 Wharton’s jelly (WJ)-derived MSCs (WJ-MSCs), fibrosis intensity and accumulation of calcium/necrotic fibers were significantly decreased. To elucidate the mechanism of this effect, we verified the effect of WJ-MSCs in a hydrogen peroxide-induced fibrosis myotubes model. In addition, we demonstrated that matrix metalloproteinase-1 (MMP-1), a paracrine factor, is critical for this anti-fibrotic effect of WJ-MSCs. These findings demonstrate that WJ-MSCs exert anti-fibrotic effects against skeletal muscle fibrosis, primarily via MMP-1, indicating a novel target for the treatment of muscle diseases, such as DMD.

Sign in / Sign up

Export Citation Format

Share Document